AxSpA-IBD: Half of Patients Show TNFi AxSpA Remission.

Published Date: 27 May 2023

Adalimumab, as opposed to another TNFi, appeared to have a greater ability to induce axial spondyloarthritis remission in patients with IBD who had had it for less than five years and in those who were taking it.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?

2.

Health of Myeloma Patient's Marriage Tied to Recovery After Transplant

3.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

4.

In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.

5.

From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot